Age: 33.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Vaccination site pain, Vaccination site pruritus, Vision blurred
Clinical narrative: uveitis on the right eye, rated 3 out of 4 in terms of worseness on a scale of 1-4; synechiae forming on the back of the right eye.; stabbing pain that woke me up/It would hurt if I move my eye to look at something; very red eye assumed pink eye; blurry vision; watery eye; mild chills; tiredness; raised bump - at injection site; small light colored bruise remained; bump that itched - at injection site; red bump- at injection site; painful bump- at injection site; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of UVEITIS (uveitis on the right eye, rated 3 out of 4 in terms of worseness on a scale of 1-4) and IRIS ADHESIONS (synechiae forming on the back of the right eye.) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 014M20A and 031A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 14-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 11-Apr-2021, the patient experienced VACCINATION SITE MASS (raised bump - at injection site), VACCINATION SITE BRUISING (small light colored bruise remained), VACCINATION SITE PRURITUS (bump that itched - at injection site), VACCINATION SITE ERYTHEMA (red bump- at injection site) and VACCINATION SITE PAIN (painful bump- at injection site). On 12-Apr-2021, the patient experienced CHILLS (mild chills) and FATIGUE (tiredness). On 13-Apr-2021, the patient experienced EYE PAIN (stabbing pain that woke me up/It would hurt if I move my eye to look at something), OCULAR HYPERAEMIA (very red eye assumed pink eye), VISION BLURRED (blurry vision) and LACRIMATION INCREASED (watery eye). On 14-Apr-2021, the patient experienced UVEITIS (uveitis on the right eye, rated 3 out of 4 in terms of worseness on a scale of 1-4) (seriousness criterion medically significant) and IRIS ADHESIONS (synechiae forming on the back of the right eye.) (seriousness criterion medically significant). On 13-Apr-2021, CHILLS (mild chills) and FATIGUE (tiredness) had resolved. On 14-Apr-2021, UVEITIS (uveitis on the right eye, rated 3 out of 4 in terms of worseness on a scale of 1-4), IRIS ADHESIONS (synechiae forming on the back of the right eye.), EYE PAIN (stabbing pain that woke me up/It would hurt if I move my eye to look at something) and OCULAR HYPERAEMIA (very red eye assumed pink eye) had resolved. On 23-Apr-2021, VACCINATION SITE BRUISING (small light colored bruise remained) had resolved. At the time of the report, VISION BLURRED (blurry vision), LACRIMATION INCREASED (watery eye), VACCINATION SITE MASS (raised bump - at injection site), VACCINATION SITE PRURITUS (bump that itched - at injection site), VACCINATION SITE ERYTHEMA (red bump- at injection site) and VACCINATION SITE PAIN (painful bump- at injection site) outcome was unknown.            No concomitant medication included. Treatment medication included Steroid drops PredForte four times daily, dilating drop twice daily.  Company Comment: Based on the information provided which includes a temporal association between the use of mRNA-1273 vaccine and onset of the reported events, a causal relationship cannot be excluded. Vaccination site pruritus, vaccination site erythema, vaccination site pain, chills and fatigue are consistent with the product safety profile.   This case was linked to MODERNATX, INC.-MOD-2021-089596 (E2B Linked Report).; Sender's Comments: Based on the information provided which includes a temporal association between the use of mRNA-1273 vaccine and onset of the reported events, a causal relationship cannot be excluded. Vaccination site pruritus, vaccination site erythema, vaccination site pain, chills and fatigue are consistent with the product safety profile MODERNATX, INC.-MOD-2021-089596:Case for dose 1